NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain

被引:312
|
作者
Huang, BH [1 ]
Eberstadt, M [1 ]
Olejniczak, ET [1 ]
Meadows, RP [1 ]
Fesik, SW [1 ]
机构
[1] ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064
关键词
D O I
10.1038/384638a0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
PROGRAMMED cell death (apoptosis) mediated by the cytokine receptor Fas is critical for the removal of autoreactive T cells(1), the mechanism of immune privilege(2,3), and for maintenance of immune-system homeostasis(4). Signalling of programmed cell death involves the self-association of a conserved cytoplasmic region of Fas called the death domain(5-7) and interaction with another death-domain-containing protein, FADD(8) (also known as MORT1)(9). Although death domains are found in several proteins(10), their three dimensional structure and the manner in which they interact is unknown, Here we describe the solution structure of the Fas death domain, as determined by NMR spectroscopy, The structure consists of six antiparallel, amphipathic a-helices arranged in a novel fold, From the structure and from site-directed mutagenesis, we have identified the region of the death domain involved in self-association and binding to the downstream signalling partner FADD.
引用
收藏
页码:638 / 641
页数:4
相关论文
共 50 条
  • [21] Looking beneath the surface: The cell death pathway of Fas/APO-1 (CD95)
    Stanger, BZ
    MOLECULAR MEDICINE, 1996, 2 (01) : 7 - 20
  • [22] Evaluation of CD95 (APO-1/FAS) and the CD95 ligand in acute myelogenous leukemia
    Mestice, A
    Specchia, G
    Coppi, MR
    Palumbo, G
    Carluccio, P
    Attolico, I
    Quarta, A
    Liso, V
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 74 - 74
  • [23] Sensitivity and resistance to apoptosis in the APO-1 (Fas/CD95) system
    Debatin, KM
    ONKOLOGIE, 1996, 19 : 3 - 5
  • [24] CD95 (APO-1/Fas) and Parkinson's disease - Reply
    Zipp, F
    Martin, R
    Dichgans, J
    Weller, M
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 426 - 426
  • [25] APO-1/Fas(CD95)分子研究进展
    陈俊,郭坤元
    国外医学(免疫学分册), 1996, (02) : 61 - 65
  • [26] Fas antigen/APO-1 (CD95) expression on myeloma cells
    Shima, Y
    Nishimoto, N
    Yoshizaki, K
    Kishimoto, T
    LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 521 - +
  • [27] Fas (CD95/Apo-1) expression and apoptosis in myelodysplasia.
    Bouscary, D
    DeVos, J
    FontenayRoupie, M
    Melle, J
    Jondeau, K
    Picard, F
    Dreyfus, F
    Guesnu, M
    BLOOD, 1996, 88 (10) : 2544 - 2544
  • [28] Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases
    Nozawa, K
    Kayagaki, N
    Tokano, Y
    Yagita, H
    Okumura, K
    Hasimoto, H
    ARTHRITIS AND RHEUMATISM, 1997, 40 (06): : 1126 - 1129
  • [29] Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma
    Gross, N
    Balmas, K
    Brognara, CB
    Tschopp, J
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (01): : 111 - 114
  • [30] Expression of APO-1 (Fas/CD95) on human hematopoietic cells and sensitivity towards APO-1 induced cell death.
    Stahnke, K
    Kleihauer, E
    Debatin, KM
    BLOOD, 1995, 86 (10) : 581 - 581